The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Real-world safety of trastuzumab deruxtecan in Japanese patients with gastric cancer
Hisato Kawakami, MD, PhD, Tohoku University, Sendai, Japan, comments on the real-world incidence of interstitial lung disease (ILD) and severe adverse events associated with trastuzumab deruxtecan in Japanese patients with HER2-positive gastric cancer. Dr Kawakami notes that a post-marketing survey study of over 1,000 patients found an ILD incidence of 9.6% and severe adverse events of 2.3%, with a potential risk factor for ILD, including older age and prior lung disease. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
